ALVO OAKTREE ACQUISITION CORP II

Niðurstaða aðalfundar Alvotech árið 2025

Niðurstaða aðalfundar Alvotech árið 2025

Aðalfundur Alvotech S.A. („félagsins“) fór fram 25. júní 2025. Fundurinn var haldinn í Lúxemborg, á skrifstofu lögfræðistofunnar Arendt við Avenue John F. Kennedy 41A.  

Allar tillögur á dagskrá fundarins voru samþykktar. Ítarleg fundargerð og niðurstöður atkvæðagreiðslu verða birtar á vef félagins á sérstöku svæði fyrir gögn aðalfundarins:

Fjárfestatengsl Alvotech

Benedikt Stefánsson, forstöðumaður

Viðhengi



EN
25/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility

Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company’s existing senior secured term loan facility, including GoldenTree Asset Management (collectively, the “Lenders”), have agreed to reduce the rate of interest on its existing senior secured term loan facility (the “Facility”). The agreement will lower Alvotech’s inter...

 PRESS RELEASE

Lánveitendur Alvotech lækka vexti á langtímaskuldum félagsins

Lánveitendur Alvotech lækka vexti á langtímaskuldum félagsins REYKJAVIK (26. júní 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að bandaríska eignastýringarfyrirtækið GoldenTree Asset Management hafi boðist til að lækka vexti á langtímaskuldum félagsins í samráði við hóp alþjóðlegra stofnanafjárfesta sem standa að baki lánveitingunum. Vaxtakostnaður Alvotech næstu 12 mánuði lækkar um rúman milljarð króna. Ákvörðun lánveitendanna staðfestir frábæran árangur í rekstri Alvotech og aukna tiltrú á rekstur félagsins. „Alvotech er í dag með flest hliðstæðulyf í þróun í heiminum samkvæ...

 PRESS RELEASE

Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility

Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company’s existing senior secured term loan facility, including GoldenTree Asset Management (collectively, the “Lenders”), have agreed to reduce the rate of interest on its existing senior secured term loan facility (the “Facility”). The agreement will lower Alvotec...

 PRESS RELEASE

Alvotechs långivare sänker räntan på senior säkerställd lånefacilitet

Alvotechs långivare sänker räntan på senior säkerställd lånefacilitet REYKJAVIK, ISLAND (26 juni 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, ”Bolaget”), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för patienter över hela världen, meddelade idag att långivarna till Bolagets befintliga seniora säkerställda lånefacilitet, inklusive GoldenTree Asset Management (gemensamt kallade ”Långivarna”), har sänkt räntan på Bolagets befintliga seniora säkerställda lånefacilitet (”Faciliteten”). Överenskommelsen medför en minskning av Alv...

 PRESS RELEASE

Main Results of 2025 Annual and Extraordinary General Meeting

Main Results of 2025 Annual and Extraordinary General Meeting The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: Alvotech Investor Relations Benedikt Stefansson

ResearchPool Subscriptions

Get the most out of your insights

Get in touch